ZyVersa Therapeutics Inc.
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.1104
- Today's High:
- $0.1288
- Open Price:
- $0.1104
- 52W Low:
- $0.11
- 52W High:
- $25
- Prev. Close:
- $0.111
- Volume:
- 8145052
Company Statistics
- Market Cap.:
- $4.34 million
- Book Value:
- 0.848
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -59.59%
- Return on Equity TTM:
- -4011.44%
Company Profile
ZyVersa Therapeutics Inc. had its IPO on 2022-12-12 under the ticker symbol ZVSA.
The company operates in the Healthcare sector and Biotechnology industry. ZyVersa Therapeutics Inc. has a staff strength of 7 employees.
Stock update
Shares of ZyVersa Therapeutics Inc. opened at $0.11 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.11 - $0.13, and closed at $0.13.
This is a +15.77% increase from the previous day's closing price.
A total volume of 8,145,052 shares were traded at the close of the day’s session.
In the last one week, shares of ZyVersa Therapeutics Inc. have slipped by -8.87%.
ZyVersa Therapeutics Inc.'s Key Ratios
ZyVersa Therapeutics Inc. has a market cap of $4.34 million, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months ZyVersa Therapeutics Inc.’s revenue was $0 with a gross profit of $0 and an EBITDA of $-16161874. The EBITDA ratio measures ZyVersa Therapeutics Inc.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, ZyVersa Therapeutics Inc.’s operating margin was 0% while its return on assets stood at -59.59% with a return of equity of -4011.44%.
In Q2, ZyVersa Therapeutics Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
ZyVersa Therapeutics Inc.’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-7.47 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ZyVersa Therapeutics Inc.’s profitability.
ZyVersa Therapeutics Inc. stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.
ZyVersa Therapeutics Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $31.99 million
- Total Liabilities
- $10.48 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
ZyVersa Therapeutics Inc. ended 2024 with $31.99 million in total assets and $0 in total liabilities. Its intangible assets were valued at $31.99 million while shareholder equity stood at $20.06 million.
ZyVersa Therapeutics Inc. ended 2024 with $0 in deferred long-term liabilities, $10.48 million in other current liabilities, 2367.00 in common stock, $-86978221.00 in retained earnings and $11.90 billion in goodwill. Its cash balance stood at $228693.00 and cash and short-term investments were $228693.00. The company’s total short-term debt was $59,625 while long-term debt stood at $0.
ZyVersa Therapeutics Inc.’s total current assets stands at $1.12 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $8.14 million and inventory worth $0.
In 2024, ZyVersa Therapeutics Inc.'s operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, ZyVersa Therapeutics Inc. paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.13
- 52-Week High
- $25
- 52-Week Low
- $0.11
- Analyst Target Price
- $
ZyVersa Therapeutics Inc. stock is currently trading at $0.13 per share. It touched a 52-week high of $25 and a 52-week low of $25. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.18 and 200-day moving average was $0 The short ratio stood at 0.22 indicating a short percent outstanding of 0%.
Around 5443.8% of the company’s stock are held by insiders while 2796.7% are held by institutions.
Frequently Asked Questions About ZyVersa Therapeutics Inc.
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.